Shanghai Henlius doses first patient in Phase 2/3 HLX43 trial for advanced squamous NSCLC in China

PUBT·05/28/2026 08:31:28

Listen to the news

Shanghai Henlius Biotech dosed the first patient in an international phase 2/3 trial of HLX43, alone or with EGFR antibody HLX07, versus docetaxel.
The study targets advanced or metastatic squamous NSCLC in Chinese Mainland with disease progression following first-line therapy.
Earlier pooled NSCLC findings from HLX43 studies will be presented at the 2026 ASCO Annual Meeting from May 29 to June 2, 2026.
Those results showed encouraging anti-tumor activity across patient subgroups, with a tolerability profile described as manageable.
No comparable HLX43-HLX07 combination has been cleared for sale anywhere globally.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Henlius Biotech Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260528-12174089), on May 28, 2026, and is solely responsible for the information contained therein.

FAQ

Fee Schedule Open Account Deposit & Withdrawal Trading

Terms & Conditions

Client Agreement Privacy Policy Data Disclaimer Security Tips

About Webull

About us Webull Promotions Contact information Announcements

Contact Number :+852 3852 8500

Monday 7:00 AM - Saturday 9:00 AM (HKT)

Service Email :service@webull.hk

Online Support: Monday - Friday: 9:00 - 16:00; 22:30 - 5:00 (HKT)

Business Cooperation :marketinghk@webull.hk

Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.

Language

English